Subtotal $0.00
Shop Now
An Ozempic rash is uncommon, and most skin problems with GLP-1 medicines are small, local reactions where the pen was used. In Ozempic’s placebo-controlled trials, injection site reactions such as discomfort or redness were reported in 0.2% of people. Rash and hives appear in the label only among reports received after approval, alongside rare serious allergic reactions such as anaphylaxis and angioedema (swelling under the skin). Rates are higher with some related medicines: about 3% of people on Mounjaro and 6% to 8% on Zepbound had injection site reactions in trials. A mild, itchy red patch at the site is usually something to mention to a pharmacist. Swelling of the face, lips, tongue or throat, trouble breathing, or a widespread severe rash needs emergency care.
Peptide Labs does not sell Ozempic, Wegovy, Mounjaro, Zepbound or any prescription drug. This article summarizes FDA labels. For other effects reported across the class, see our guide to GLP-1 medicine side effects.
Key Takeaways
- Ozempic trials: injection site reactions in 0.2% of people, mostly discomfort or redness.
- Rash and hives on Ozempic appear only in postmarketing reports, so their frequency is unknown.
- Wegovy adult trials: injection site reactions in 1.4% versus 1% on placebo.
- Mounjaro: 3.2% versus 0.4% on placebo; Zepbound: 6% to 8% versus 2%.
- Reactions were more common in people who developed antibodies to the medicine.
- Facial or throat swelling, breathing trouble or fainting means stop the medicine and get emergency help.
Ozempic rash: what the label says
The Ozempic prescribing information (revised May 2026) mentions skin reactions in two places. Its clinical trial section reports injection site reactions in 0.2% of people in placebo-controlled trials, giving injection-site discomfort and erythema (redness) as examples. Its postmarketing section lists anaphylaxis, angioedema, rash and urticaria (hives) under hypersensitivity. Postmarketing reports are sent in voluntarily from a population of unknown size, so the label says they cannot reliably show how often a reaction happens or prove the drug caused it.
The label also carries a formal warning about serious hypersensitivity reactions. It tells prescribers to stop Ozempic if such a reaction occurs, and Ozempic should not be used by anyone who has had a serious allergic reaction to semaglutide or its other ingredients. It advises caution in people who have had anaphylaxis or angioedema with another GLP-1 medicine, because it is unknown whether they are more likely to react to Ozempic.
Ozempic injection site reaction rates compared with related drugs
An Ozempic injection site reaction is less common in trial data than reactions to some other medicines in the class. The table lists what each U.S. label reports. Trials differed in size, length and population, so the numbers are a rough guide rather than a head-to-head comparison.
| Drug (approved use) | Injection site reactions | Other allergic or skin findings | Label revision |
|---|---|---|---|
| Ozempic (type 2 diabetes) | 0.2% in placebo-controlled trials | Rash, hives, anaphylaxis and angioedema in postmarketing reports | May 2026 |
| Wegovy injection, adults (weight management) | 1.4% vs 1% on placebo | Anaphylaxis, angioedema, rash and hives in postmarketing reports | June 2026 |
| Wegovy injection, ages 12 and older | Not reported separately | Rash 3% vs 0%; hives 3% vs 0% on placebo | June 2026 |
| Mounjaro (type 2 diabetes) | 3.2% vs 0.4% on placebo | Allergic reactions 3.2% vs 1.7%, sometimes severe, such as hives and eczema | August 2026 |
| Zepbound (weight management) | 6% to 8% vs 2% on placebo | Allergic reactions within a day 2.1% vs 0.4%; later reactions 3.5% vs 2.7% | August 2026 |
The Zepbound label counts bruising, redness, itching, pain and rash at the site as injection site reactions, and it says most allergic reactions in its trials were skin reactions such as rash and itching. Severe allergic reactions occurred in 0.1% of people on Zepbound and in no one on placebo. More detail by drug is in our semaglutide guide, our tirzepatide guide and our Zepbound guide.
Wegovy injection site reactions and antibodies
Wegovy injection site reactions in adult trials included itching, redness, inflammation, hardening (induration) and irritation at the site, in 1.4% of people versus 1% on placebo, so most would have occurred with any injection. Teenagers seemed more prone to skin reactions: in the trial of ages 12 and older, rash and hives were each reported in 3% on Wegovy and none on placebo. Our Wegovy side effect guide covers the full list.
Some people make antibodies against these medicines, and the labels link those antibodies with more skin and allergic reactions:
- Wegovy: allergic reactions in 16% of adults with antibodies to semaglutide versus 7% without.
- Mounjaro: injection site reactions in 4.6% of adults with antibodies to tirzepatide versus 0.7% without.
- Zepbound: injection site reactions in 11.3% of people with antibodies versus 1% without.
Antibody testing is not part of routine care, and the labels do not say antibodies make the medicine stop working. The point is simply that reactions are more likely in some people than others.
Ozempic itching: local reaction or allergy?
Ozempic itching limited to a small area around the spot where the pen was used, with some redness or a mild bump, fits the pattern of a local injection site reaction. Itching spread across the body, hives in several places, or a rash that keeps expanding points more toward an allergic reaction, which the labels treat as a more serious matter. Not every rash is caused by the GLP-1 medicine: new skin care products, other medicines, infections and heat can all cause skin changes, which is why a clinician should look at anything that spreads.
The Mounjaro and Zepbound Instructions for Use also name two longer-term skin changes at injection sites: lipodystrophy (pits or thickened skin) and localized cutaneous amyloidosis (lumps under the skin), and explain how site choice affects that risk. Firm lumps that do not fade, warmth, spreading redness, pus or fever can signal a skin infection and should be checked promptly.
When an Ozempic rash is an emergency
The Ozempic Medication Guide tells people to stop using the medicine and get medical help right away for symptoms of a serious allergic reaction:
- Swelling of the face, lips, tongue or throat.
- Problems breathing or swallowing.
- Severe rash or itching.
- Fainting or feeling dizzy.
- A very rapid heartbeat.
Call 911 for breathing trouble, throat swelling or collapse. The Wegovy, Mounjaro and Zepbound labels carry similar warnings. Because these are weekly medicines that stay in the body for some time, symptoms can need monitoring, and a prescriber will decide whether the medicine can be used again.
What to do about a mild reaction
For a small, itchy or red patch that is not spreading, these general steps can help you and your care team:
- Show the reaction to a pharmacist or prescriber, or take dated photos if it fades before an appointment.
- Ask a pharmacist before using an anti-itch cream or antihistamine, so it fits your other medicines.
- Go back over the Instructions for Use with your pharmacist; it is the only official source for how your pen should be used, and it differs between products.
- Avoid scratching, which can break the skin and raise infection risk.
- Tell your prescriber about any past reactions to other GLP-1 medicines.
- Report suspected side effects to the manufacturer or to the FDA’s MedWatch program, as each label invites.
Products sold outside the approved supply chain add uncertainty. The FDA says it does not review compounded drugs for safety, effectiveness or quality, and some compounded semaglutide uses salt forms that differ from the approved active ingredient; see our article on compounded GLP-1 products.
Frequently Asked Questions
Can Ozempic cause a rash?
Rash and hives are listed in the Ozempic label among reports received after approval, so the rate is unknown. Injection site reactions were reported in 0.2% of people in trials.
What does an Ozempic injection site reaction look like?
The label gives discomfort and redness as examples. Related labels add itching, swelling, hardening, bruising, pain or rash at the spot where the pen was used.
Is Ozempic itching a sign of allergy?
Itching limited to the site is usually a local reaction. Widespread itching, hives, or swelling of the face or throat may be allergic and needs prompt medical help.
How common are Wegovy injection site reactions?
In adult weight-management trials, 1.4% of people on Wegovy had injection site reactions versus 1% on placebo.
Are skin reactions more common with Mounjaro or Zepbound?
Their labels report higher rates: 3.2% on Mounjaro versus 0.4% on placebo, and 6% to 8% on Zepbound versus 2%.
When should I go to the emergency room for an Ozempic rash?
Go right away or call 911 for swelling of the face, lips, tongue or throat, trouble breathing or swallowing, fainting, a very fast heartbeat or a severe spreading rash.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: Semaglutide Side Effects: What the Ozempic, Wegovy and Rybelsus Labels Say, GLP-1 Side Effects: What Every GLP-1 Drug Label Warns About, Wegovy Side Effects: Injection, Pill, Teens and Wegovy HD.